BioPharmSignal logoBioPharmSignal

Biotech News

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

Spero Therapeutics (SPRO)Spero TherapeuticsEarnings

On track for topline data from SPR720 Phase 2a proof-of-concept trial in treatment-naive and treatment-experienced non-refractory NTM-PD patients, expected in 2H 2024

Enrollment ongoing in PIVOT-PO, a pivotal Phase 3 clinical trial of oral tebipenem HBr in cUTI

Received FDA Fast Track designation for SPR206 for...

Related news

SPROSpero Therapeutics2026-05-13 21:05 EST

Spero Therapeutics Announces First Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

ANTXAN2 Therapeutics2026-05-11 20:01 EST

AN2 Therapeutics Reports First Quarter 2026 Financial Results and Recent Business and Scientific Highlights

ANTXAN2 Therapeutics2026-08-11 20:00 EST

AN2 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business and Scientific Highlights

VIRIVirios Therapeutics2026-08-13 12:30 EST

Dogwood Therapeutics Announces Second Quarter 2026 Financial Results

VIRIVirios Therapeutics2026-05-14 12:30 EST

Dogwood Therapeutics Announces First Quarter 2026 Financial Results

COCPCocrystal Pharma2026-05-15 12:00 EST

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

ABUSArbutus2026-05-13 11:30 EST

Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update

AVIRAtea2026-05-12 20:06 EST

Atea Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update

IMNNImunon2026-05-12 12:00 EST

IMUNON Reports First Quarter 2026 Financial Results and Provides Business Update

View all latest news

Spero Therapeutics

Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to...

Recent company news

SPROSpero Therapeutics2026-08-12 21:01 EST

Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update

SPROSpero Therapeutics2026-08-05 21:05 EST

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SPROSpero Therapeutics2026-08-04 21:01 EST

Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

SPROSpero Therapeutics2026-07-27 13:00 EST

Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer

Stock data

Close
1.22 USD
Market cap
163.86M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States